Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026Budoprutug clinical trials ongoing in pMN, ...

Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...

Continued clinical progress follows regulatory authorization to advance study First patient continues to show dramatic vision restoration GREENSBORO, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Precise ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute ...

Coordinating groups of underwater robots is difficult because communication below the surface is slow and unreliable. GPS ...

Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with pulmonary ...

The San Diego-based biotech firm Gossamer Bio announced today that it still intends to seek a regulatory path forward with ...